The U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult…
Press
Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis (MS)… Click here…
September 12, 2019 | Beverly Hills, CA — Genentech, a member of the Roche Group, announced positive results from one of its phase III clinical…
Featured Videos
